Page 130 - 2026华南国际口腔展电子会刊
P. 130

19.2D18-3   Rigenera HBW

              地址 /Address:Via Sestriere, 17 Candiolo Torino Italy
              邮编 /Postal Code:10060
              电话 /Tel:0039 0119934508
              邮箱 /Email:info@rigenerahbw.com
              网址 /Website:www.rigenerahbw.com

              HBW 是一家以科技驱动的公司,作为一家医疗器械开发和制造公司,其拥有意大利
           制造、突破性创新、独一无二的专利技术 Rigenera®。Rigenera® 是再生医学领域一款
           有效、强大且安全的工具,通过注射微移植悬浮液,提供一种促进组织再生的快 速、安
           全和有效的方法 . HBW 的核心业务是基于 RIGENERA® 技术的生产,该技术由一 款医
           疗器械“Rigeneracons”、专用电机转子及相关配件 (Sicurlid、底座和 Sicurstick 适配
           器 ) 组成,用于将设备连 接到电机。Rigenera® 是一套革命性的前沿系统,该系统基于 在
           “Rigeneracons”一次性无菌医疗设备 (MD) 内对人体组织 ( 患者活检组织 ) 进行温和、
           可控的机械分解,以 80 rpm 的磁力稳定旋转和精细的过热控制,使细胞存活率达到 70%-
           90%。得益于这项技术,我们能够利用一次性无菌医疗设备,在不使用酶和 / 或添加剂的
           情况下,通过机械分解从自体和同源组织中产生微移植悬浮液 ( 微移植悬浮液最小尺寸为
           80 微米 )。
              HBW is a technology-driven company operating as a medical device developer and
           manufacturer, distinguished by Made in Italy quality, breakthrough innovation, and its
           unique patented technology, Rigenera®.
              Rigenera® is an effective, powerful, and safe tool in the field of regenerative
           medicine. Through the injection of a micrograft suspension, it provides a fast, safe, and
           effective method to p+A4:O4romote tissue regeneration.
              HBW’s core business is based on the production of the RIGENERA® technology,
           which consists of a medical device called Rigeneracons, a dedicated motor with a
           magnetic rotor, and related accessories (Sicurlid, base, and Sicurstick adapter) used to
           connect the device to the motor.
              Rigenera® is a revolutionary, cutting-edge system based on the gentle and
           controlled mechanical disaggregation of human tissues (patient biopsy tissue) inside the
           sterile single-use medical device Rigeneracons. The system uses magnetically stabilized
           rotation at 80 rpm and precise overheating control, allowing a cell viability rate of 70%–
           90%.
              Thanks to this technology, it is possible to generate micrograft suspensions from
           autologous and homologous tissues through mechanical disaggregation, using sterile
           single-use medical devices, without the use of enzymes and/or additives (the minimum
           micrograft size is 80 micrometers).





           4
   125   126   127   128   129   130   131   132   133   134   135